4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Akeso, Inc. (9926) operates in the Biotechnology industry and is headquartered in Zhongshan, China with about 4,082 employees. Its market capitalization is roughly HK$102 billion. In the fiscal year ended 2025-12-31, 9926 reported CNY 3.1B in revenue and (CNY 1.1B) in net income.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
Interactive charts & full statements → Open the 9926 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 3.1B | CNY 2.1B | CNY 4.5B | CNY 838M | — |
| Gross Profit | CNY 2.4B | CNY 1.8B | CNY 4.4B | CNY 744M | — |
| Operating Income (EBIT) | (CNY 848M) | (CNY 504M) | CNY 2.2B | (CNY 1.2B) | — |
| Net Income | (CNY 1.1B) | (CNY 514M) | CNY 2.0B | (CNY 1.2B) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 16.0B | CNY 12.8B | CNY 9.2B | CNY 5.5B | — |
| Total Liabilities | CNY 7.1B | CNY 6.0B | CNY 4.7B | CNY 2.9B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9926 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms